Enorama Pharma AB (SE:ERMA)

:ERMA

ERMA

Enorama Pharma AB

RESEARCH TOOLSreports

Want to see SE:ERMA full AI Analyst Report?

Enorama Pharma AB (ERMA) Price & Analysis

0 Followers

ERMA Stock Chart & Stats

kr1.91

-kr0.30(-12.50%)

At close: Mar 06 4:00 PM EST

kr1.91

-kr0.30(-12.50%)

Day’s Range― - ―

52-Week Rangekr0.21 - kr3.58

Previous CloseN/A

Volume29.79K

Average Volume (3M)4.35K

Market Cap

kr33.34M

Enterprise Valuekr15.58M

Total Cash (Recent Filing)kr17.76M

Total Debt (Recent Filing)kr0.00

Price to Earnings (P/E)―

Beta0.65

Next Earnings

Aug 26, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.91

Shares Outstanding74,588,684

10 Day Avg. Volume2,975

30 Day Avg. Volume4,348

Financial Highlights & Ratios

PEG Ratio-0.06

Price to Book (P/B)-5.66

Price to Sales (P/S)48.45

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Partnering-based Business ModelEnorama’s model focuses on developing patented NRT formulations and monetizing via licensing, milestone and royalty deals. Structurally this is asset-light, reduces need for a large commercial footprint, and lets product economics scale through partner distribution if agreements are secured.

Low Financial LeverageVery low or near-zero debt materially reduces insolvency risk and interest burden, preserving capacity to raise funds for development. Over a multi-month horizon this improves financial optionality and reduces fixed-cost pressure compared with highly leveraged peers.

Demonstrated Gross-profit PotentialRecording positive gross profit in 2024 indicates the underlying formulations can deliver favorable unit economics. If Enorama can restore volumes or secure partner manufacturing terms, that demonstrated profitability provides a credible path to sustainable margins with scale.

Bears Say

Persistent Cash BurnConsistent and sizable negative operating cash flow implies ongoing funding needs and reliance on external capital. Over 2–6 months this pressures runway, forces dilutive financing or deal concessions, and limits the company’s ability to advance development or commercialize independently.

Negative Shareholders' EquityNegative equity reflects cumulative losses and weak capitalisation, constraining borrowing capacity and increasing financing cost. Structurally this heightens vulnerability to funding shocks and may require equity issuance or asset sales to restore balance sheet health.

Small, Declining Revenue And Worsening MarginsA small, shrinking revenue base and deteriorating gross/operating margins indicate weak commercial traction and limited operating leverage. Over months this undermines partner negotiating power, slows scale-up potential, and increases the challenge of moving to sustained profitability.

ERMA FAQ

What was Enorama Pharma AB’s price range in the past 12 months?

Enorama Pharma AB lowest stock price was kr0.21 and its highest was kr3.58 in the past 12 months.

What is Enorama Pharma AB’s market cap?

Enorama Pharma AB’s market cap is kr33.34M.

When is Enorama Pharma AB’s upcoming earnings report date?

Enorama Pharma AB’s upcoming earnings report date is Aug 26, 2026 which is in 93 days.

How were Enorama Pharma AB’s earnings last quarter?

Enorama Pharma AB released its earnings results on May 20, 2026. The company reported -kr0.17 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.17.

Is Enorama Pharma AB overvalued?

According to Wall Street analysts Enorama Pharma AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Enorama Pharma AB pay dividends?

Enorama Pharma AB does not currently pay dividends.

What is Enorama Pharma AB’s EPS estimate?

Enorama Pharma AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Enorama Pharma AB have?

Enorama Pharma AB has 74,588,684 shares outstanding.

What happened to Enorama Pharma AB’s price movement after its last earnings report?

Enorama Pharma AB reported an EPS of -kr0.17 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 23.333%.

Which hedge fund is a major shareholder of Enorama Pharma AB?

Currently, no hedge funds are holding shares in SE:ERMA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Enorama Pharma AB

Enorama Pharma AB (publ), a pharmaceutical company, develops, manufactures, and sells medicated chewing gum containing proven generic substances in Sweden. It offers nicotine chewing gum for smoking cessation and medical cannabis chewing gums for non-pharma applications, as well as for other applications, such as oromucosal drug delivery and allergic rhinitis. The company is based in Malmö, Sweden.